SEGLENTIS: The first and only co-crystal formulation with built-in multimodal analgesia1,2

SEGLENTIS puts 4 complementary mechanisms of analgesic and anti-inflammatory properties in 1 tablet using a unique co-crystal formulation1

SEGLENTIS combines a Schedule IV opioid* and an NSAID, providing broad-spectrum central and peripheral analgesia compared to each individual agent alone1,2

SEGLENTIS leverages 4 complimentary mechanisms of analgesia1

The MOA of celecoxib is believed to be due to

  • Inhibition of COX-2

The MOA of tramadol is believed to be due to

  • Weak inhibition of serotonin reuptake
  • Partial agonism of μ-opioid receptor
  • Weak inhibition of norepinephrine reuptake

Celecoxib exhibits analgesic, anti-inflammatory, and antipyretic properties. The MOA of celecoxib is believed to be due to inhibition of prostaglandin synthesis, primarily via inhibition of COX-2.1

Although the tramadol hydrochloride MOA is not completely understood, the M1 metabolite is believed to be primarily responsible for the analgesic effect on the μ-opioid receptor.1

SEGLENTIS co-crystal formulation features a unique PK profile1,4,5

The rate and extent of absorption for celecoxib were observed earlier and higher, whereas the rate of tramadol was delayed and gradual vs open combination1,4,5

In a Phase 1, randomized, single‑dose, open‑label, 4‑period, 4‑sequence, crossover absorption study at a single center in the United States, the following were compared1,5:

  • The PK of 2 active pharmaceutical ingredients from SEGLENTIS (celecoxib and tramadol) with those of the individual reference products (used in the United States) alone or in free combination

PK parameters1*

This table is adapted from the PK table shown in the SEGLENTIS Prescribing Information.

SEGLENTIS optimizes its anti-inflammatory component vs standard coadministration of ingredients.1,5

SEGLENTIS minimizes daily opioid exposure to maintain benefits over risk per CDC recommendations.1,2,6

SEGLENTIS co-crystal formulation features a unique PK profile1,4,5

The rate and extent of absorption for celecoxib was observed earlier and higher, and the rate of tramadol was delayed and gradual vs open combination1,4,5

Consistent observations of the PK profiles of SEGLENTIS components vs individual agents or when coadministered4*

Treatment arms5

  • 200-mg SEGLENTIS (112-mg celecoxib/88-mg tramadol hydrocholoride)
  • 100-mg tramadol hydrochloride IR
  • 100-mg celecoxib
  • 100-mg celecoxib + 100-mg tramadol hydrochloride IR (individual agents coadministered)

View efficacy of SEGLENTIS over 48 hours

Explore data

References: 1. Seglentis [prescribing information]. Montgomery, AL: Kowa Pharmaceuticals America, Inc.; October 2021. 2. Viscusi ER, de Leon-Casasola O, Cebrecos J, et al. Celecoxibtramadol co-crystal in patients with moderate-to-severe pain following bunionectomy with osteotomy: a phase 3, randomized, double-blind, factorial, active- and placebo-controlled trial. Pain Pract. 2023;23(1):8-22. doi:10.1111/papr.13136. Epub 2022 Jul 8. PMID: 35686380 3. United States Drug Enforcement Administration. Drug scheduling. Accessed March 28, 2023. https://www.dea.gov/drug-information/drug-scheduling 4. Almansa C, Frampton CS, Vela JM, Whitelock S, Plata-Salamán CR. Co-crystals as a new approach to multimodal analgesia and the treatment of pain. J Pain Res. 2019;12:2679-2689. doi:10.2147/JPR.S208082 5. Cebrecos J, Carlson JD, Encina G, et al. Celecoxib-tramadol co-crystal: a randomized 4-way crossover comparative bioavailability study. Clin Ther. 2021;43(6):1051-1065. doi:10.1016/j.clinthera.2021.04.002 6. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR Recomm Rep. 2022;71(3):1-95. doi:10.15585/mmwr.rr7103a1